[Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]

Rosness TA, Zinöcker S, Brurberg KG
Record ID 32018001640
Original Title: Vurdering av tester for PD-L1 ved urotelialt karsinom: en forenklet metodevurdering
Authors' objectives: To evaluate commercial PD-L1 tests for use in treatment of urothelial carcinoma
Authors' results and conclusions: We included two systematic reviews. None of the included systematic reviews were limited to PD-L1 testing of urothelial carcinoma. Studies on PD-L1 testing of non-small cell lung cancer show high degree of agreement between test results from 22C3, 28-8 and SP263. SP142 showed somewhat lower agreement compared to the other tests. There was high degree of agreement between how PD-L1 expression was assessed by different pathologists and in different laboratories. This rapid HTA summarizes the degree of agreement between commercially available PD-L1 tests. The HTA doesn’t provide any conclusions on the effectiveness of various treatment strategies in the treatment of urothelial carcinoma in adults.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Norway
MeSH Terms
  • Programmed Cell Death 1 Receptor
  • Lung Neoplasms
  • Urinary Bladder Neoplasms
  • Urologic Neoplasms
  • Cell Cycle Checkpoints
  • Carcinoma, Transitional Cell
  • Immunotherapy
  • B7-H1 Antigen
Organisation Name: Norwegian Institute of Public Health
Contact Address: P.O. Box 222 Skoyen, N-0123, Oslo
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.